Affimed: Positive Takeaways From AFM-13 Focused R&D Day; Multiple Catalysts Ahead Including Potential Partnership With PD1/PD-L1 Company For AFM13 Combo Trial [Seeking Alpha]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Seeking Alpha
As the previous article provided a broad overview of Affimed and the opportunity for investors , this follow-up will concentrate almost exclusively on takeaways from the AFM13-focused R&D Day. Extreme market weakness on the R&D day overshadowed a positive event for Affimed ( AFMD ) that was mainly focused on the clinical path for AFM13 (as opposed to a deep-dive on their entire pipeline ), post encouraging FDA meetings and positive data shared at ASH 2018. Affimed’s T Cell Engager Platform: AFM11 And AMV564 Before covering the key takeaways from the R&D Day, here is a quick note on Affimed’s T cell engager platform, which was mentioned just twice during the presentation by Affimed’s CEO Dr. Hoess. Once briefly while he was covering the pipeline slide, and then again briefly during his closing remarks while discussing Affimed’s cash runway extending to 2021 with ~$139 million in cash post the Genentech deal; he noted “lots of data coming in 2019/2020 either based
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck (MRK) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
- TME Pharma Publishes 2023 Financial Results and Provides Operating Update [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 4/25/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- MRK's page on the SEC website